1 4

Outstanding results | Exclusive pricing | Import collaborators

Most Demanding

Customers Feedback

  • Ashraf

    Mujhe lagta hai ke is ka asar thoda slow hai, lekin kaam karta hai.

  • Noman

    Mujhe is tablt ka as such koi side effect to nahi hua, highly recommended.

  • Imran

    Ye product har jagah easily available hona chahiye.

  • سلمان

    Pair text with an image to focus on your chosen product, collection, or blog post. Add details on availability, style, or even provide a review.

  • Jawad

    Iski price thodi zyada hai, lekin quality achi hai.

  • Muneer

    product quality ke lehaz se bohot behtareen hy.

  • S.Naqi

    Ye goli jaldi asar karti hai aur bohot asaan hai use karna.

  • Ashar Ali

    Nice product highly recommended

  • Arslan

    US card best item hy or jabardast kam krti hy

  • Salman multani

    setisfy ... fast delivery service

  • Asad

    wonderfull experiance thanks

1 11

News Release

  • Sanofi and Lilly announce licensing agreement for Cialis® (tadalafil) OTC

    PARISandINDIANAPOLIS,May 28, 2014/PRNewswire/ --Sanofi(EURONEXT: SAN and NYSE: SNY) andEli Lilly and Company(NYSE: LLY) today announced an agreement to pursue regulatory approval of nonprescription Cialis (tadalafil). Cialis is currently available by prescription only worldwide for the treatment of men with erectile dysfunction (ED).

    Read now 

  • Identification

    Summary

    Tadalafil is a phosphodiesterase 5 inhibitor used to treat erectile dysfunction, benign prostatic hyperplasia, and pulmonary arterial hypertension.

    Read now 

  • Tadalafil in the treatment of erectile dysfunction

    The treatment for erectile dysfunction (ED) was revolutionized with the development of phosphodiesterase type 5 (PDE5) inhibitors. Tadalafil (Cialis®; Eli Lilly and Company, Indianapolis, IN, USA) is the newest and most versatile PDE5 inhibitor in the clinical armamentarium for the treatment of ED. Its most unique characteristic is its long half-life of 17.5 hours, which lends itself to a longer therapeutic window with on-demand dosing and effective steady-state plasma concentrations with once-daily dosing. Clinical trials have proven its safety and efficacy with both dosing strategies for all severities and etiologies of ED, including difficult-to-treat ED.

    Read now 

  • Zuellig Pharma acquires Cialis® (Tadalafil)

    Singapore, 5 February 2024

    Zuellig Pharma, a leading healthcare solutions company in Asia, has announced that it has completed the acquisition of two brands, Cialis® (Tadalafil) and Alimta® (Pemetrexed), from Eli Lilly and Company (“Lilly”) for select ASEAN markets, including Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, Philippines and Thailand, via its wholly-owned subsidiary, Zanovex Pte. Ltd. (“Zanovex”). Zanovex will own the trademarks and marketing authorisations, and license manufacturing know-how for Alimta®, an established chemotherapy drug for the treatment of a certain type of non-small cell lung cancer and malignant pleural mesothelioma, and Cialis®, a leading men’s health product for the treatment of erectile dysfunction.

    Read now